

Enterobacteriaceae

- The Enterobacteriaceae are a large group of **gram-negative rods** whose natural habitat is the intestinal tract of humans and animals.
- The family includes many genera (*Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Klebsiella*, *Serratia*, *Proteus*, *Citrobacter*, *Providencia*, *Morganella*, *Yersinia* and others). Enterobacteriaceae also called **coliforms**.
- The enteric bacteria are sometimes found as part of the normal flora of the upper **respiratory** and **genital tracts**. When clinically important infections occur, they are usually caused by *E coli*, but the other enteric bacteria are causes of **hospital-acquired infections** and occasionally cause **community-acquired infections**.

Escherichia coli: Pathogenesis

1. Urinary Tract Infection:

- *E coli* are the most common cause of urinary tract infection.
- The **symptoms and signs** include:
 - Urinary frequency, dysuria, hematuria, and pyuria.
 - Flank pain is associated with upper tract infection.
 - Urinary tract infection can result in bacteremia with clinical signs of sepsis.

2. *E coli*-Associated Diarrheal Diseases These *E coli* are classified by the characteristics of their virulence properties:

a- Enterotoxigenic *E coli* (ETEC) is a common cause of "**traveler's diarrhea**" and a very important cause of diarrhea in **infants**. ETEC adherence to the epithelial cells of the small bowel. Some strains of ETEC produce **exotoxin** and other produce **enterotoxin**. Its subunit B attaches to the **GM₁ ganglioside** at the brush border of epithelial cells of the small intestine and facilitates the entry of subunit A into the cell, where the latter activates **adenylyl cyclase**. This markedly increases the local concentration of **cyclic adenosine monophosphate (cAMP)**, which results in intense and prolonged **hypersecretion** of water and chlorides and inhibits the reabsorption of sodium. The gut lumen is distended with fluid, and hypermotility and diarrhea ensue, lasting for several days.



- 2

Diagnostic Laboratory Tests:

1. **Clinical:** Clinical diagnosis.
2. **Laboratory:**
 - a/ cultur on selective media (e.g., MacConkey agar, eosin-methylene blue [EMB] agar.
 - b. **Biochemical** identification.
 - c. **Serologic** testing.

Treatment:

- Sulfonamides, ampicillin, cephalosporins, fluoroquinolones (ciprofloxacin), and aminoglycosides (streptomycin).
- **Surgical correction.**
- **Restoration** of fluid and electrolyte balance.
- For the **prevention of traveler's diarrhea** daily ingestion of bismuth subsalicylate suspension and tetracyclines or (ciprofloxacin or trimethoprim-sulfamethoxazole) for prophylaxis.

The Shigellae: they produce **bacillary dysentery**

Pathogenesis & Pathology:

- Shigella infections are limited to the **gastrointestinal** tract; bloodstream invasion is rare.
- The essential pathologic process is invasion of the **mucosal epithelial** cells (eg, M cells).
- **Multiplication** and spread within the epithelial cell cytoplasm, and passage to adjacent cells.
- **Microabscesses** in the wall of the large intestine and terminal ileum lead to **necrosis** of the mucous membrane, superficial **ulceration**, bleeding, and formation of a "**pseudomembrane**" on the ulcerated area. This consists of fibrin, leukocytes, cell debris, a necrotic mucous membrane, and bacteria. As the process subsides, **granulation** tissue fills the ulcers and **scar** tissue forms.

Clinical Findings

Enterobacteriaceae

- After **incubation period (1–2 days)**, there is a sudden onset of abdominal pain, fever, and watery diarrhea.
- The number of **stools increases**; they are less liquid but often contain mucus and blood.
- **rectal spasms**
- In **adult** cases, fever and diarrhea subside spontaneously in 2–5 days. However, in **children and the elderly**, loss of water and electrolytes may lead to **dehydration**, acidosis, and even **death**.
- On **recovery**, most persons shed dysentery bacilli for only a short period, but a few remain **chronic** intestinal **carriers** and may have **recurrent** bouts of the disease.

Immunity: Injection of **killed shigellae** stimulates production of antibodies in serum but fails to protect humans against infection. **IgA** antibodies in the gut important in limiting reinfection; these may be stimulated by **live attenuated** strains given orally as experimental vaccines.

Treatment: Ciprofloxacin, ampicillin, doxycycline, and trimethoprim-sulfamethoxazole.

Epidemiology, Prevention, & Control

Shigellae are transmitted by "food, fingers, feces, and flies" from person to person. Most cases of shigella infection occur in children under 10 years of age. Control efforts (1) **sanitary control** of water, food, and milk; sewage disposal; and fly (2) **isolation** of patients and disinfection of excreta; (3) detection of **subclinical cases** and carriers, and (4) **antibiotic** treatment of infected individuals.

The Salmonella

They cause **enteritis**, **systemic infection**, and **enteric fever**.

Pathogenesis & Clinical Findings:

Among the host factors those resistances to salmonella infection are **gastric acidity**, **normal intestinal** microbial flora, and local **intestinal immunity**.

1. The "Enteric Fevers" (Typhoid Fever):

Enterobacteriaceae

- The ingested salmonellae reach the **small intestine**, from which they enter the **lymphatic** and then the **bloodstream**.
- They are carried by the blood to **many organs**
- The organisms multiply in intestinal lymphoid tissue and are **excreted in stools**.
- After an incubation period of **10–14 days**, fever, malaise, headache, constipation, bradycardia, and myalgia occur. The fever rises to a high plateau, and the **spleen and liver** become enlarged. **Rose spots**, usually on the skin of the abdomen or chest, are seen briefly in rare cases.
- The **white blood cell count** is normal or low. The chief complications of enteric fever were **intestinal hemorrhage** and perforation, and the mortality rate was 10–15%.
- The principal lesions are **hyperplasia** and **necrosis** of lymphoid tissue (eg, Peyer's patches), **hepatitis**, focal necrosis of the liver, and inflammation of the **gallbladder**, **periosteum**, **lungs**, and other organs.

2. Bacteremia with Focal Lesions

3. Enterocolitis

Immunity: Reinfection may occur but is often milder than the first infection. However, relapses may occur in 2–3 weeks after recovery in spite of antibodies.

Treatment

- **Replacement** of fluids and electrolytes is essential.
- **Antimicrobial** therapy with ampicillin, trimethoprim-sulfamethoxazole, or a third-generation cephalosporin.
- In most carriers, the organisms persist in the **gallbladder** (particularly if gallstones are present) and in the biliary tract. Some chronic carriers have been cured by ampicillin alone, but cholecystectomy must be combined with drug treatment.

Carriers: some individuals continue to **harbor salmonellae** in their tissues for variable lengths of time. Three percent of survivors of typhoid become permanent carriers, harboring the organisms in the **gallbladder**, **biliary tract**, or, rarely, the intestine or urinary tract.

Sources of Infection:

Enterobacteriaceae

- Water Contamination with feces.
- Milk and Other Dairy Products
- Meats and Meat Products, Eggs.
- Animal Dyes: Dyes (eg, carmine) used in drugs, foods, and cosmetics.
- Household Pets: dogs, cats, etc.

Prevention & Control:

- **Sanitary** measures.
- **Infected** poultry, meats, and eggs must be thoroughly cooked.
- **Carriers** must not be allowed to work as food handlers.
- Two injections of acetone-killed bacterial suspensions of *Salmonella* Typhi, followed by a booster injection some months later.
- Oral administration of a **live avirulent** mutant strain of *Salmonella* Typhi in areas of high endemicity.

Pseudomonas

Pathogenesis

This organism is widely distributed in **nature** and is commonly present in **moist** environments in hospitals. It is pathogenic only when introduced into **areas devoid of normal defenses**, e.g.,

- Disruption of mucous membrane and skin.
- Usage of intravenous or urinary catheters.
- Neutropenia (as in cancer therapy).

P. aeruginosa is **invasive** and toxigenic. It attaches to and colonizes the mucous membrane or skin, invades locally, and produces **systemic diseases** and **septicemia**.

Clinical Diseases:

1. Infection of wounds and burns.
2. Meningitis
3. Tracheobronchitis and pulmonary infection
4. Eye infections
5. Ear infections otitis externa (swimmers); malignant in diabetic patients.
Chronic otitis media
6. Urinary tract infection

7. Sepsis

Laboratory Diagnosis:

- Specimen: skin lesions, pus, urine, blood, spinal fluid, sputum.
- Culture.
- Several subtyping methods, including phage typing and molecular typing, are available for epidemiologic purposes.

Treatment:

- **Combined antibiotic** therapy is required to avoid resistance
- Avoid using **inappropriate antibiotics**, which can suppress the normal flora and permit overgrowth of resistant *Pseudomonads*.

Prevention and Control:

- *Pseudomonas* spp. normally inhabits soil, water, and vegetation and can be isolated from the skin, throat, and stool of healthy persons.
- Spread is via contact with fomites or by ingestion of contaminated food and water.
- High risk population: patients receiving broad-spectrum antibiotics, with leukemia, burns, cystic fibrosis, and immunosuppression.

Control:

- Patients at high risk should not be admitted to a ward where cases of pseudomonas infection are present.
- Patients infected with *P.aeruginosa* should be isolated.
- Sterilize all instruments, apparatus, and dressing.
- Monitor clinically relevant isolates of *P. aeruginosa* by a suitable typing system to identify epidemic strains.

Reference: Lange Medical Microbiology, 24th Edition: Jawetz, Melnick, & Adelberg/ Chapter 16. Enteric Gram-Negative Rods (Enterobacteriaceae).